Brendan P. Lovasik

1 month ago | onlinelibrary.wiley.com | Brendan P. Lovasik |Abraham J. Matar |Jakob Habib |David Faber

1 Introduction The presence of strong anti-donor antibodies represents a formidable barrier in solid organ transplantation. For patients on the waiting list, broad levels of sensitization considerably prolong waiting times, and preformed anti-donor antibodies increase the risk of antibody-mediated rejection (ABMR) after receipt of a transplant [1]. For patients with an existing graft, de novo antibody formation poses the risk of graft injury and potential graft loss.

Aug 27, 2024 | onlinelibrary.wiley.com | Andrew Adams |David Faber |Brendan P. Lovasik |Abraham J. Matar

1 Introduction Developing an immunosuppressive regimen that uses clinically available drugs and consistently prolongs graft and recipient survival in preclinical models has been an elusive goal in preventing the clinical application of xenotransplantation [1-4]. Recent experience shows that successful outcomes in non-human primates (NHPs) can be achieved if the recipient level of anti-pig antibodies is low.